(2) Rubicon expression could be a prognostic marker in different types of cancers and (3) Therapies that could inhibit Rubicon expression could be incorporated into clinical trials as drugs that regulate LAP during phagocytosis of apoptotic tumor cells. Here, TGFB1 is linked to neoplasm.